About Us

why choose us

Why EndoShunt

Vision

To end preventable abdominal hemorrhage death and improve patient outcomes.

Mission

Giving trauma surgeons the gift of time so they can give trauma patients the gift of life.

Our Values

Proactive

Taking ownership of what must get done.

Caring

A holistic perspective in improving outcomes.

Agile

Quick teamwork facing new challenges and opportunities.

The Problem

Trauma surgeons are placed in an untenable position trying to save patients as they hemorrhage but often not having the time required to access the injured site before the patient exsanguinates. In these cases, the trauma community has recently adopted the use of endovascular balloon occlusion of the aorta in order to control blood pressure around the heart and brain, but no solution other than surgical intervention currently exists for the targeted control of bleeding.

A significant need exists for the rapid and targeted control of hemorrhage that can be rapidly implemented to buy time for surgical repair of the injuries.

The Market

The hemorrhage treatment market is upwards of $60 Billion USD. EndoShunt’s beachhead market is around $366 Million USD (Based on initial indications of use in trauma field). Validated through customer discovery interviews and the American College of Surgeons Trauma Quality Improvement Program (TQIP) A significant driver of the growth for the hemorrhage treatment market has been minimally invasive endovascular solutions such as EndoShunt.

Numerous needs exist in multiple additional fields of medicine, expanding the market size far beyond the confines of the trauma industry.

Annual Traumatic Abdominal Hemorrhage

Annual EndoShunt Indications in Trauma

Annual EndoShunt’s Lives Saved

$ 0 M

EndoShunt’s Trauma Market

EndoShunt is The solution

EndoShunt effectively controls hemorrhage from an injury while maintaining blood flow to the rest of the body, providing trauma surgeons with the time they need to perform definitive repairs.

EndoShunt is a novel endovascular delivery system and hemorrhage control tool allowing surgeons to place a temporary length adjustable shunt within the major abdominal vessels.

welcome to EndoShunt

EndoShunt is Nearing Market Readiness

EndoShunt iterative development has yielded fully functional manufactured prototypes with proven efficacy at preventing hemorrhage in benchtop and in vivo simulated traumatic vascular injury studies.

EndoShunt’s regulatory strategy has been built based on the expertise of Health Policy Associated and experts involved in the intended predicate’s FDA clearance. EndoShunt will begin their pursuit of 510(k) clearance following a Q-sub meeting in 2023.

EndoShunt is the solution

We provide trauma surgeons with a way to rapidly gain targeted
control of abdominal hemorrhage.

Development

EndoShunt has completed rounds of prototype iteration, and currently has fully functional manufactured prototypes. Benchtop and in-vivo tests on simulated traumatic vascular injuries have validated the initial efficacy of EndoShunt and current work is underway to reduce the catheter size prior to design freeze. As a medical technology, EndoShunt has partnered with Health Policy Associates to develop a regulatory strategy, including a high probability of achieving an accelerated regulatory path through the 510 K predicate pathway. Advisors from the predicate device are actively assisting in the regulatory strategy.

Market Validation

EndoShunt led our cohort through the NSF ICorps program to kick off our founding, completing 300+ interviews of surgeons, value analysis committee members…

Intellectual Property

EndoShunt’s patent portfolio includes the non-provisional utility patent US-20220305241-A1, along with provisional applications US17656,390, and US63/166,133. The company holds all rights to these patents, ensuring its pioneering endovascular shunt technology for critical blood vessel conditions is safeguarded.

Address

Our Offices

Chicago

965 West Chicago Ave, Chicago, IL 60642

Chicago

Nashville

2100 West End Ave Suite 1300, Nashville, TN 37203

Nashville

Delaware

704 N. King Street Suite 500, P. O. Box 1031, Wilmington DE 19899

Delaware